Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $74,264.60 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,654 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $44.90, for a total transaction of $74,264.60. Following the completion of the sale, the chief executive officer now owns 673,064 shares of the company’s stock, valued at approximately $30,220,573.60. The trade was a 0.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Twist Bioscience Stock Down 2.1 %

NASDAQ:TWST opened at $48.17 on Friday. The firm’s fifty day simple moving average is $45.61 and its 200 day simple moving average is $46.72. The stock has a market cap of $2.86 billion, a P/E ratio of -13.38 and a beta of 1.82. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently modified their holdings of the stock. Thrivent Financial for Lutherans purchased a new stake in Twist Bioscience in the third quarter worth about $43,992,000. Point72 Asset Management L.P. lifted its stake in shares of Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after purchasing an additional 613,057 shares during the period. Fred Alger Management LLC boosted its position in shares of Twist Bioscience by 720.7% during the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after purchasing an additional 575,080 shares in the last quarter. State Street Corp grew its stake in Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares during the period. Finally, Wellington Management Group LLP raised its holdings in Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Barclays lowered their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Wolfe Research initiated coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. Evercore ISI lifted their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Scotiabank increased their price objective on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. Finally, Robert W. Baird lifted their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $51.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.